CD274 and cancer: Previous studies have indicated that the activation of type I interferon signaling can boost the response to anti-PD-1/anti-PD-L1 therapy in various cancers by upregulating antigen presentation, converting ‘cold tumors’ to ‘hot tumors’ and increasing PD-L1 expression [6, 41], including NSCLC [42–44].